

Technology Appraisal Committee A Interests Register

Topic: Delgocitinib for treating moderate to severe chronic hand eczema [ID6408]

Publication Date: 01 October 2025

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|-----------------|----------------------|------------------------|--|------------------------------|---|
| David McAlister | TAC Committee Member | Financial | Access trial data from some of these companies (or their competitors) for my academic research - see https://vivli.org/resources/public-disclosures/ for details. David has received individual-level clinical trial data from competitor organisations via the Vivli repository. | 30/07/2025 08/05/2025 | It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal. |
| Mariana Bacelar | TAC Committee Member | Professional Interests | The EAG for the project is BMJ TAG which Mariana is part of | 07/07/2025 | It was agreed that Mariana's declaration would prevent her from participating in discussions on this appraisal. |
| Richard Woolf | Clinical Expert | Direct - Financial | Personal financial interest (last 12 months): Paid clinical work as consultant dermatologist: Cleveland Clinic London. Paid lectures/symposia - Abbvie, Janssen, Leo Pharma, Novartis and Sanofi. Advisory board – Abbvie | 04/06/2025 | It was agreed that Dr Woolf's declaration would not prevent him from providing expert advice to the committee. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|--------------|----------------|------------------------|--|-------------------|---|
| | | | <p>and Leo Pharma. Educational support to attend meetings - Abbvie, Almirall, Novartis and Sanofi.</p> <p>Leo pharma paid speaker work; Jun 2024, £700</p> <p>Leo pharma paid advisory work looking at the current treatment pathway for patients with chronic hand eczema (consensus piece)*; Dec 2023, £2000</p> <p>*related to delgocitinib</p> | | |
| | | Direct – non-financial | Departmental research funding [clinical trials] (last 3 years): Abbvie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Leo Pharma, Janssen, Novartis, Pfizer and Sanofi. | 04/06/2025 | |
| Pippa Cousen | Patient Expert | Direct - Financial | <p>Payment for PI DELTA 1 & 3 trials</p> <p>Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema</p> | 04/06/2025 | It was agreed that Ms Cousen's declaration would not prevent her from |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|----------------|----------------|----------------------|---|-------------------|--|
| | | | (DELTA 1): multicentre, randomised, controlled, double-blind, phase 3 trial. Open label extension trial (DELTA 3) | | providing expert advice to the committee. |
| Andrew Proctor | Patient Expert | Indirect - Financial | <p>Manufacturer corporate member for several years. Annual corporate membership fee £15,000 plus VAT. The charity's Corporate Membership Scheme allows company partners to demonstrate public support for the important work of the Society. The funding helps pay for the charity's core operating costs.</p> <p>Regarding manufacturers of comparator products: Lilly corporate member annual fee for this of £15,000 plus VAT. AbbVie corporate member annual fee for this of £20,000 plus VAT, Almirall corporate member annual fee £20,000 plus VAT. Almirall also provided unrestricted funding of €10,000 under the company's Global 'You Feel Well' Challenge initiative.</p> | 04/06/2025 | It was agreed that Mr Proctor's declaration would not prevent him from providing expert advice to the committee. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------|-------------------|------------------|-------------------------|----------------------|----------|
| | | | | | |
| | | | | | |